Your browser is no longer supported. Please, upgrade your browser.
Settings
MRTX Mirati Therapeutics, Inc. daily Stock Chart
MRTX [NASD]
Mirati Therapeutics, Inc.
Index- P/E- EPS (ttm)-2.77 Insider Own0.30% Shs Outstand30.79M Perf Week-6.04%
Market Cap1.23B Forward P/E- EPS next Y-3.79 Insider Trans- Shs Float30.79M Perf Month-33.59%
Income-76.80M PEG- EPS next Q-0.87 Inst Own98.85% Short Float12.14% Perf Quarter-27.45%
Sales9.50M P/S129.67 EPS this Y33.70% Inst Trans2.10% Short Ratio7.24 Perf Half Y41.13%
Book/sh8.28 P/B4.83 EPS next Y-15.20% ROA-46.60% Target Price57.89 Perf Year157.30%
Cash/sh8.45 P/C4.73 EPS next 5Y- ROE-51.60% 52W Range12.26 - 65.35 Perf YTD119.23%
Dividend- P/FCF- EPS past 5Y1.50% ROI- 52W High-38.77% Beta1.75
Dividend %- Quick Ratio14.50 Sales past 5Y- Gross Margin- 52W Low226.48% ATR3.53
Employees51 Current Ratio14.50 Sales Q/Q- Oper. Margin- RSI (14)30.40 Volatility8.77% 8.89%
OptionableYes Debt/Eq0.00 EPS Q/Q-27.40% Profit Margin- Rel Volume1.23 Prev Close41.86
ShortableYes LT Debt/Eq0.00 EarningsOct 31 BMO Payout- Avg Volume516.00K Price40.01
Recom2.00 SMA20-14.56% SMA50-24.36% SMA200-2.34% Volume636,091 Change-4.42%
Jul-09-18Reiterated Oppenheimer Outperform $35 → $62
Mar-12-18Initiated Barclays Overweight $44
Jan-09-18Reiterated H.C. Wainwright Buy $17 → $21
Nov-14-17Upgrade Leerink Partners Mkt Perform → Outperform
Oct-12-17Resumed H.C. Wainwright Buy $20
Sep-19-17Initiated Oppenheimer Outperform $18
Sep-15-17Reiterated Leerink Partners Mkt Perform $7 → $9
Nov-17-16Initiated H.C. Wainwright Buy $12
Jun-06-16Reiterated Wedbush Outperform $29 → $27
Jun-06-16Downgrade Leerink Partners Outperform → Mkt Perform
Jun-06-16Downgrade Jefferies Buy → Hold
May-24-16Reiterated Wedbush Outperform $41 → $29
May-09-16Reiterated Wedbush Outperform $45 → $41
Mar-02-16Initiated Sun Trust Rbsn Humphrey Buy $32
Feb-17-16Resumed Jefferies Buy
Jan-13-16Upgrade Citigroup Neutral → Buy
Nov-23-15Initiated Citigroup Neutral
Oct-19-15Initiated Barclays Overweight $50
Sep-17-15Downgrade Piper Jaffray Overweight → Neutral $50 → $45
Jun-01-15Reiterated Wedbush Outperform $34 → $45
Oct-21-18 05:10AM  Mirati Therapeutics Announces Updated Data From Ongoing Clinical Trial Of Single Agent Sitravatinib At The 2018 ESMO Congress PR Newswire
Oct-15-18 04:30PM  Mirati Therapeutics To Provide Updated Sitravatinib Clinical Data At The European Society For Medical Oncology (ESMO) 2018 Congress And Conduct Investor Call PR Newswire
Oct-09-18 09:41AM  3 Biotech Stocks With Major Incoming Catalysts Motley Fool
Oct-08-18 05:29PM  Nobel Prize for Cancer Immunotherapy & Biotech ETFs to Buy Zacks
Sep-14-18 11:15AM  Mirati Therapeutics Inc (NASDAQ:MRTX): Time For A Financial Health Check Simply Wall St.
Aug-29-18 04:30PM  Mirati Therapeutics To Participate In Oncology Panels At The 2018 Citi Biotech Conference PR Newswire
Aug-24-18 07:11AM  Should Invesco DWA SmallCap Momentum ETF (DWAS) Be on Your Investing Radar? Zacks
Aug-16-18 04:30PM  Mirati Therapeutics Announces Presentation Of KRAS G12C Chemistry Advances At The 255th American Chemical Society (ACS) National Meeting And Exposition PR Newswire
Aug-01-18 06:53PM  Mirati: 2Q Earnings Snapshot Associated Press
04:15PM  Mirati Therapeutics Reports Second Quarter Financial Results PR Newswire
09:15AM  Should Invesco DWA SmallCap Momentum ETF (DWAS) Be on Your Investing Radar? Zacks
Jul-28-18 08:00AM  How to Invest in Clinical-Stage Biotechs Without Losing Money Motley Fool
Jul-24-18 04:59PM  Mirati Therapeutics To Present Updated Sitravatinib Clinical Data At The European Society For Medical Oncology (ESMO) 2018 Congress PR Newswire
Jul-17-18 07:35AM  Breakfast Technical Briefing on Mirati Therapeutics and Three Other Additional Biotech Stocks ACCESSWIRE +5.11%
Jun-25-18 04:30PM  Mirati Therapeutics Added to Russell 2000® Index PR Newswire
Jun-15-18 09:20AM  Should PowerShares DWA SmallCap Momentum Portfolio (DWAS) Be on Your Investing Radar? Zacks
Jun-11-18 04:15PM  Mirati Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire
Jun-07-18 11:26AM  Here's Why Mirati Therapeutics, Inc. Is Rising Today Motley Fool +18.40%
08:00AM  Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock PR Newswire
Jun-06-18 04:01PM  Mirati Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire
May-31-18 04:30PM  Mirati To Present New Data In Renal Cell Carcinoma From Ongoing Phase 1b Clinical Trial Of Single Agent Sitravatinib At The 2018 ASCO Annual Meeting PR Newswire
May-30-18 04:46PM  Mirati Therapeutics To Present At Jefferies 2018 Global Healthcare Conference PR Newswire
May-29-18 08:44AM  Mirati Therapeutics (MRTX) Soars: Stock Adds 13.6% in Session Zacks
May-07-18 05:03PM  Mirati: 1Q Earnings Snapshot Associated Press
04:10PM  Mirati Therapeutics Reports First Quarter Financial Results PR Newswire
May-02-18 12:01PM  Harry Boxers four biotech stocks to watch today MarketWatch
Apr-30-18 04:47PM  Can These Top-Performing Biotech Stocks Keep Climbing? Motley Fool
Apr-26-18 11:19AM  Harry Boxers two biotechnology stocks to watch today MarketWatch
Apr-24-18 04:15PM  Mirati Therapeutics Announces Progress Of Lead Programs And Provides Updated Positive Clinical Trial Results For Immuno-Oncology Combination Trials PR Newswire
Mar-09-18 08:26AM  Did Mirati Therapeutics Incs (NASDAQ:MRTX) Recent Earnings Growth Beat The Trend? Simply Wall St. +11.79%
Mar-08-18 04:30PM  Mirati Therapeutics Reports Fourth Quarter And Full-Year 2017 Financial Results PR Newswire
Mar-07-18 04:30PM  Mirati Therapeutics To Present At Upcoming Healthcare Conferences PR Newswire
Feb-21-18 07:35AM  Recent Analysis Shows EchoStar, Toro, Genesee & Wyoming, Express Scripts Holding, D.R. Horton, and Mirati Therapeutics Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Feb-08-18 04:15PM  Mirati Therapeutics To Present At Leerink Partners 7th Annual Global Healthcare Conference PR Newswire -10.52%
Jan-11-18 10:54AM  Nektar Notches New Highs As Stock Triples In Two Months Forbes +6.67%
Jan-10-18 11:39AM  Harry Boxers three health-care stocks to watch today MarketWatch +14.17%
Jan-08-18 06:00AM  BeiGene and Mirati Therapeutics Announce Exclusive License Agreement for Sitravatinib in the Asia Pacific Region GlobeNewswire -8.02%
Nov-20-17 04:15PM  Mirati Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares PR Newswire +5.80%
Nov-16-17 07:06PM  Cramer's lightning round: After Opko Health's quarter, it... CNBC Videos +35.23%
08:45AM  Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock PR Newswire
Nov-15-17 04:01PM  Mirati Therapeutics Announces Proposed Public Offering Of Common Stock PR Newswire +6.44%
Nov-13-17 04:15PM  Mirati Therapeutics Announces Advancement Of First-In-Class Opportunities With Sitravatinib And KRAS Inhibitor Programs PR Newswire
Nov-08-17 08:30AM  Market Trends Toward New Normal in ONEOK, ServiceNow, Mirati, ImmunoCellular, United Technologies, and USG Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Nov-02-17 05:49AM  Mirati reports 3Q loss Associated Press +7.09%
Nov-01-17 04:30PM  Mirati Therapeutics Reports Third Quarter 2017 Financial Results PR Newswire
Oct-18-17 12:52PM  Four Biotech And Health Care Breakouts Forbes
Oct-12-17 04:45PM  Mirati Therapeutics' Mocetinostat Included In Stand Up To Cancer's Cutting-Edge Clinical Trial Initiative For NSCLC Patients PR Newswire
03:32PM  4 Biotech Stocks Initiated At Buy: Acceleron, Tesaro, Mirati, Fate Benzinga
Sep-19-17 04:30PM  Mirati Therapeutics To Present At Upcoming Healthcare Conferences PR Newswire
01:31PM  A Peek Into The Future For Mirati Therapeutics Benzinga
Sep-18-17 08:45AM  Options Traders Expect Huge Moves in Mirati Therapeutics (MRTX) Stock Zacks
03:00AM  Mirati Therapeutics Joins Elite Club Of Stocks With RS Ratings Over 90 Investor's Business Daily
Sep-15-17 12:07PM  Is It Too Late To Buy Mirati Therapeutics Inc (MRTX)? Simply Wall St. +135.79%
10:42AM  Mirati Therapeutics Sitravatinib Data, Explained Benzinga
09:24AM  Mirati Skyrockets On Positive Data - Biotech Movers TheStreet.com
08:27AM  Mirati Therapeutics' stock soars on heavy volume after positive cancer treatment trial results MarketWatch
Sep-14-17 04:30PM  Mirati Therapeutics Presents Positive Preliminary Data From On-Going Clinical Trials Of Sitravatinib In Non-Small Cell Lung Cancer PR Newswire
Sep-06-17 02:00PM  Sitravatinib Data To Be Highlighted At The IASLC 18th World Conference on Lung Cancer PR Newswire
Aug-30-17 04:15PM  Mirati Therapeutics To Participate In Immuno-Oncology Panel Discussion At The 2017 Citi Biotech Conference PR Newswire
Aug-21-17 08:15AM  Mirati Therapeutics (MRTX) Rises: Stock Moves 10.9% Higher Zacks
Aug-03-17 07:09PM  Mirati reports 2Q loss Associated Press
04:05PM  Mirati Therapeutics Reports Second Quarter 2017 Financial Results PR Newswire
Jul-18-17 08:30AM  Mirati Therapeutics (MRTX) Rises: Stock Moves 11.5% Higher Zacks
Jul-05-17 04:15PM  Mirati Therapeutics To Host Key Opinion Leader Breakfast On Immuno-oncology Combinations On July 11 In New York PR Newswire
Jun-27-17 04:05PM  Mirati Therapeutics Announces Appointment Of Neil Reisman To The Board Of Directors PR Newswire -7.41%
May-31-17 04:15PM  Mirati Therapeutics To Present At The 2017 Jefferies Global Healthcare Conference PR Newswire -9.68%
May-04-17 06:38PM  Mirati reports 1Q loss Associated Press
04:05PM  Mirati Therapeutics Reports First Quarter 2017 Financial Results PR Newswire
Mar-27-17 04:05PM  MIRATI THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Ex
Mar-15-17 01:04PM  MIRATI THERAPEUTICS, INC. Financials +6.67%
Mar-09-17 06:46PM  Mirati reports 4Q loss Associated Press
04:22PM  MIRATI THERAPEUTICS, INC. Files SEC form 10-K, Annual Report
04:05PM  Mirati Therapeutics Reports Financial Results And Provides Business Update For The Fourth Quarter And Full Year 2016 PR Newswire
Feb-13-17 04:05PM  Mirati Therapeutics To Present At Leerink Partners 6th Annual Global Healthcare Conference PR Newswire
Feb-01-17 04:07PM  MIRATI THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers
12:21PM  5 Stocks Insiders Love Right Now TheStreet.com
12:21PM  5 Stocks Insiders Love Right Now
Jan-22-17 10:25AM  Insider Buying Slows as Trump Inauguration Takes Center Stage: Kindred Biosciences, Mirati Therapeutics, City Office REIT and More
Jan-17-17 10:50AM  Corporate Insiders at These 5 Companies Are Buying Large Sums of Stock TheStreet.com
10:50AM  Corporate Insiders at These 5 Companies Are Buying Large Sums of Stock
Jan-09-17 03:57PM  Mirati Therapeutics Sets $65M Public Offering Investopedia
03:57PM  Mirati Therapeutics Sets $65M Public Offering at Investopedia
Jan-06-17 05:12PM  MIRATI THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
07:30AM  Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock PR Newswire
Jan-05-17 04:02PM  MIRATI THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Other Events +7.27%
04:01PM  Mirati Therapeutics Provides Update On Glesatinib And Sitravatinib Clinical Trials And Pipeline Programs PR Newswire
04:01PM  Mirati Therapeutics Announces Proposed Public Offering of Common Stock PR Newswire
Dec-15-16 09:11PM  How CardConnect Corp (CCN) Stacks Up Against Its Peers at Insider Monkey
Dec-09-16 10:52AM  How Mirati Therapeutics (MRTX) Stock Stands Out in a Strong Industry +5.36%
Dec-07-16 05:25AM  Is Mirati Therapeutics, Inc. (MRTX) Going to Burn These Hedge Funds? at Insider Monkey
Dec-01-16 08:42AM  Mirati Therapeutics, Inc. :MRTX-US: Earnings Analysis: Q3, 2016 By the Numbers : December 1, 2016
Nov-17-16 07:23AM  Coverage initiated on Mirati Therapeutics by H.C. Wainwright +5.26%
Nov-03-16 07:01PM  Mirati reports 3Q loss -5.94%
04:17PM  MIRATI THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:10PM  Mirati Therapeutics Reports Financial Results And Provides Business Update For The Third Quarter 2016 PR Newswire
Oct-04-16 07:30AM  Mirati Therapeutics Appoints Chris LeMasters To Role Of Executive Vice President And Chief Business Officer PR Newswire
Sep-29-16 04:07PM  MIRATI THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exh
07:30AM  Mirati Therapeutics Announces Appointment Of Dr. Bruce L.A. Carter To Board Of Directors PR Newswire
Sep-22-16 01:10PM  5 Stocks Under $10 That Could Make You a Lot of Money
Sep-20-16 12:15PM  Mirati Therapeutics, Inc. :MRTX-US: Earnings Analysis: Q2, 2016 By the Numbers : September 20, 2016
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops targeted therapeutics to address the genetic, epigenetic, and immunological promoters of cancer. The company is involved in developing sitravatinib, an oral spectrum-selective kinase inhibitor, which is in Phase II clinical for the treatment of solid tumor; and in Phase Ib clinical trial to treat non-small cell lung cancer (NCSLC) patients with CBL, chromosome 4q12, and RET genetic alterations, as well as mocetinostat, an orally administered spectrum-selective Class 1 histone deacetylase inhibitor that is in Phase II clinical trial in combination with durvalumab for the treatment of patients with NSCLC. Its preclinical development stage product candidate include KRAS G12C inhibitor program to address mutations and tumors. The company has a collaboration and license agreement with BeiGene, Ltd. to develop manufacture and commercialize sitravatinib. It also has collaboration with Astex Pharmaceuticals, Inc. and Merck & Co., Inc.; and Array BioPharma, Inc. to develop and commercialize products. Mirati Therapeutics, Inc. is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BAUM CHARLES MPresident & CEOAug 24Option Exercise17.4111,486199,97162,418Aug 24 07:00 PM
BAUM CHARLES MPresident & CEOAug 23Option Exercise8.5051,810440,385102,742Aug 24 07:00 PM
BAUM CHARLES MPresident & CEOAug 23Sale57.5551,8102,981,78850,932Aug 24 07:00 PM
CHEN ISANEVP, Chief Medical OfficerJul 16Option Exercise20.911,86739,03234,582Jul 17 07:00 PM
Christensen JamieSVP, Chief Scientific OfficerJun 27Option Exercise5.504,99927,4958,393Jun 28 07:00 PM
Christensen JamieSVP, Chief Scientific OfficerJun 27Sale49.544,999247,6653,394Jun 28 07:00 PM
Christensen JamieSVP, Chief Scientific OfficerJun 26Option Exercise5.405,20828,1238,085Jun 28 07:00 PM
Christensen JamieSVP, Chief Scientific OfficerJun 26Sale48.765,208253,9653,394Jun 28 07:00 PM
venBio Select Advisor LLC10% OwnerJun 11Buy38.85400,00015,540,0004,798,101Jun 12 01:57 PM
Boxer Capital, LLC10% OwnerJun 07Buy38.85193,0507,499,9931,565,560Jun 11 05:00 PM
CHEN ISANEVP, Chief Medical OfficerApr 25Option Exercise16.9413,038220,81731,836Apr 26 06:07 PM
Donadio Jamie ASr. VP, CFOMar 09Option Exercise17.4112,100210,66112,100Mar 13 06:00 PM
Christensen JamieSVP, Chief Scientific OfficerMar 09Option Exercise21.3922,000470,62024,877Apr 26 06:00 PM
Christensen JamieSVP, Chief Scientific OfficerMar 09Sale33.0022,000726,0402,877Apr 26 06:00 PM
Donadio Jamie ASr. VP, CFOMar 09Sale35.0012,100423,5000Mar 13 06:00 PM
Donadio Jamie ASr. VP, CFOMar 01Option Exercise6.5251,875338,06351,875Mar 02 06:08 PM
Donadio Jamie ASr. VP, CFOMar 01Sale27.1351,8751,407,1450Mar 02 06:08 PM
BAUM CHARLES MPresident & CEOFeb 23Option Exercise8.5051,810440,385100,366Feb 27 06:00 PM
BAUM CHARLES MPresident & CEOFeb 23Sale28.0351,8101,452,45850,932Feb 27 06:00 PM
Christensen JamieSVP, Chief Scientific OfficerFeb 06Option Exercise21.2223,000488,03025,877Feb 08 06:00 PM
Christensen JamieSVP, Chief Scientific OfficerFeb 06Sale30.0023,000690,0002,877Feb 08 06:00 PM
Christensen JamieSVP, Chief Scientific OfficerJan 26Option Exercise5.4012,50067,50015,377Jan 29 06:00 PM
Christensen JamieSVP, Chief Scientific OfficerJan 26Sale26.1112,500326,4232,877Jan 29 06:00 PM
Christensen JamieSVP, Chief Science OfficerJan 16Option Exercise17.4110,814188,27213,691Jan 18 05:00 PM
Christensen JamieSVP, Chief Science OfficerJan 16Sale27.0010,814291,9782,877Jan 18 05:00 PM
Christensen JamieSVP, Chief Science OfficerJan 11Option Exercise14.9514,500216,80516,895Jan 11 07:57 PM
Christensen JamieSVP, Chief Science OfficerJan 11Sale22.9914,725338,4762,877Jan 11 07:57 PM
Christensen JamieSVP, Chief Science OfficerNov 16Option Exercise8.5010,00085,00012,670Nov 17 07:00 PM
Boxer Capital, LLC10% OwnerNov 16Buy13.00400,0005,200,0003,135,966Nov 20 04:55 PM
venBio Select Advisor LLC10% OwnerNov 16Buy13.00650,0008,450,0004,360,601Nov 16 02:44 PM
Christensen JamieSVP, Chief Science OfficerNov 16Sale18.0010,275184,9502,395Nov 17 07:00 PM
Broadfin Healthcare Master Fun10% OwnerNov 16Sale18.0560,0001,083,0002,728,601Nov 20 04:11 PM
Christensen JamieSVP, Chief Science OfficerNov 02Option Exercise5.507,49941,24510,169Nov 03 07:00 PM
Christensen JamieSVP, Chief Science OfficerNov 02Sale14.007,499104,9862,670Nov 03 07:00 PM